Researchers are developing gene therapies that can target and kill cancer cells, while also exploring the use of viruses and other natural systems to design new cancer treatments. Studies have shown promising results in animal models, including a novel gene therapy approach that eradicates aggressive prostate cancer.
A clinical trial at UCSF Brain Tumor Research Center has shown promising results using the vitespen vaccine to stimulate the immune system to attack tumor cells. The vaccine, made from a patient's own tumor, induced a tumor-specific immune response in all 12 study patients.
Researchers discovered a protein made by microglia that helps accelerate tumor growth, and are looking for others. The findings have implications for both genetic and sporadic brain tumors.
A study by St. Jude Children's Research Hospital found that adults who survived childhood acute lymphoblastic leukemia (ALL) are at a higher risk of developing secondary neoplasms during adulthood. Most of these late-onset tumors are low-grade and curable, but some can cause significant health issues.
A study found that survivors of acute lymphoblastic leukemia have a significantly increased risk of secondary cancers developing over time. The cumulative incidence of secondary neoplasms increases from 4.17% at 15 years to 10.85% at 30 years, with the majority being low-grade tumors.
Researchers found that dual therapy with Avastin and chemotherapy agent irinotecan halted tumor growth up to twice as long as comparative therapies, offering a significant advance in treatment for aggressive gliomas. The study's findings may lead to new options for patients with the poorest possible prognosis.
Boston College biologists identify KetoCal as an effective alternative therapy for malignant brain cancer, slowing tumor growth and enhancing health in mice. The study found that KetoCal decreased tumor growth by 35-65% and improved survival rates compared to standard diets.
Researchers found that Olig2, a transcription factor, enables tumor growth in brain cancer by repressing cell-replication brake p21. Knocking out Olig2 function nearly eliminated tumor formation in mouse models.
AZD2171, a new angiogenesis inhibitor, has shown significant promise in treating glioblastomas by reducing tumor size and alleviating debilitating brain swelling. The treatment also appears to normalize blood vessels, creating a window of opportunity for other therapies to be more effective.
A study by St. Jude researchers found that brain tumors arise from cancer stem cells living in microscopic protective niches formed by blood vessels, disrupting these niches may block tumor growth. The team showed that targeting blood vessel cells could eliminate CSCs and prevent tumor reappearance following treatment.
Researchers found that blood vessels associated with brain tumors create a microenvironment that sustains cancer stem cells. Disrupting this microenvironment with antiangiogenic drugs reduces CSCs and arrests tumor growth.
Researchers at St. Jude Children's Research Hospital and City of Hope National Medical Center developed genetically modified stem cells that seek out and destroy even tiny tumors in the nervous system, using a chemotherapy drug that selectively targets cancer cells.
Researchers at Barrow and Arizona State University will develop new hydrogels to stimulate spinal cord growth and treat brain tumors. The studies aim to improve treatment options for patients with malignant brain tumors and spinal cord injuries, building on the center's reputation as a top neuroscience hub.
Researchers at Cedars-Sinai Medical Center identified genes that make brain cancer-causing stem cells resistant to chemotherapy and other treatments. The study found that these cells can regenerate and become even more aggressive after treatment, highlighting a potential target for new therapies.
A population-based study of 13,613 brain tumor cases in Sweden found that people with four or more siblings were twice as likely to develop a brain tumor. Children under 15 with three or more younger siblings had a two to fourfold increase in brain tumors compared to those with no siblings.
A large cohort study of over 420,000 cell phone users found no link between long-term or short-term cell phone use and an increased risk of brain tumors, salivary gland tumors, eye tumors, or leukemias. The study suggests that cell phone use is not associated with cancer risk.
Researchers at Massachusetts General Hospital found that proton beam radiation therapy achieved better tumor control for advanced adenoid cystic carcinoma of the cranial base compared to traditional radiation therapy. The study reported a 9% local recurrence rate, while traditional radiation resulted in over 70% local recurrence.
Children who survive childhood cancer are more likely to experience strokes later in life. Cranial radiation therapy increases the risk of stroke in these patients. Researchers are now exploring ways to screen and prevent strokes in high-risk survivors.
Researchers developed a nanoparticle delivery system that targets brain tumors, allowing for higher doses of drugs to be delivered while minimizing harm to healthy tissue. The technology has the potential to improve treatment outcomes and eliminate common side effects associated with photodynamic therapy.
A new study shows that shaped-beam radiosurgery can treat the smallest lung tumors, allowing patients to live disease-free for years. Researchers found that 91% of treated tumors never progressed and 25% of patients were cancer-free after three years.
Researchers at Thomas Jefferson University found that lower doses of radiation are equally effective in treating acoustic schwannomas, a benign but potentially devastating brain tumor. This treatment approach may preserve more hearing and reduce the need for surgery.
Research from the University of Minnesota found that children who received radiation for cancer are at higher risk for developing secondary brain tumors. Prolonged follow-up is crucial for early detection, and long-term screening recommendations are needed for all childhood cancer survivors.
Researchers have found that a cancer-fighting virus called VSV kills the most malignant form of brain cancer in mice, targeting invasive tumour cells. The study also discovered that delivering VSV intravenously can effectively treat malignant glioma with minimal side effects.
Childhood cancer survivors are at higher risk for developing second cancers, including CNS tumors, which can have devastating consequences. Radiation exposure is associated with a higher risk of malignant brain tumors like glioma and benign tumors like meningiomas, particularly in children under age 5.
Researchers have discovered three new subtypes of non-small-cell lung cancer tumors based on genetic patterns, which correlate with clinical outcomes such as survival rates and metastatic patterns. This finding may lead to more personalized treatment approaches for patients.
A pioneering study has found that the tumor suppressor gene p53 plays a crucial role in regulating communication between tumor cells and their surrounding stroma. The study identified 111 secreted proteins, 39 of which were enhanced and 21 inhibited by wt-p53 expression.
A team of researchers has developed a new method for targeting malignant brain tumors by inducing cancerous cells to commit suicide. The technique uses a molecule containing long, double-stranded RNA attached to epidermal growth factor (EGF) and delivered selectively to cells with high EGF receptors.
A recent study found that women who take multivitamins early in pregnancy may reduce their child's risk of developing certain types of brain tumors. The protective effect was strongest when multivitamins were taken close to conception, with a weakly significant reduction in the risk of medulloblastoma and primitive neuroectodermal tumors.
A new approach to radiotherapy and chemotherapy has significantly improved the outcome for children with high-risk medulloblastoma. The study found that this adaptive treatment can cure over 70% of children with this disease.
Researchers have combined two therapies to enhance the immune system's response against brain tumors. The treatment, called dendritic cell-interleukin-23, promotes the function of dendritic cells and memory T-cells, providing initial and long-term immunity.
Researchers at Ohio State University have discovered how a chemotherapy drug aids an anti-cancer virus in targeting brain tumors. The study found that the drug slows immune cells' activity, allowing the virus to spread and kill more cancer cells. This may lead to new treatment options for incurable human brain tumors.
Functional magnetic resonance imaging (fMRI) identifies critical brain regions prior to surgery, leading to more effective tumor removal and reduced surgical time. In 49% of cases, surgeons altered their treatment plans after fMRI findings, with no reported neurological deficits.
A small subset of glioma cells expressing higher levels of VEGF promote tumor blood vessel formation, making them a potential target for new therapies against intractable brain tumors. Targeting these cancer stem cells may block angiogenesis and prevent tumor growth.
Researchers have developed a new approach to treating gliomas, deadly brain tumors, by delivering radioactive iodine using a man-made version of scorpion venom as a carrier. The treatment targets glioma cells without affecting neighboring tissue or body organs and has shown promise in Phase I clinical trials.
Abnormal stimulation of a cellular trigger causes invasive tumor-like growths in mice, which regress upon removal. The study suggests a possible treatment for lethal brain tumors by targeting PDGFRá B cells.
Researchers found that missing portions of chromosomes can predict which patients will likely do better with therapy. Patients with tumors having deletions in chromosome locations 1p and 19q tended to live nearly two and a half times longer than those without such deletions.
Researchers develop a novel cancer vaccine delivery system using genetically modified Salmonella typhimurium that safely delivers antigens to the immune system, eliciting an immune response against cancer cells. Meanwhile, a DNA-based vaccine targeting tumor-associated fibroblasts significantly suppresses tumor growth and increases che...
Researchers have developed a new microbeam radiation therapy (MRT) technique that can deliver more lethal doses to tumors while sparing healthy tissue. The improved method uses significantly thicker microbeams and interlaces them within a well-defined target volume to increase killing potential.
Scientists discover a new compound, PI-103, that effectively inhibits the spread of brain cancer by targeting two separate steps in the signaling pathway. This dual blockade proves to be safe and effective in slowing down cancer cell proliferation in mice with human glioma cells.
Researchers have developed a new method for detecting brain tumours during surgery using a fluorescent compound, which significantly improves complete tumour removal rates (65% vs 36%) and survival rates without tumour progression (41% vs 21%). The technique has been shown to be safe with no significant difference in serious side effects.
Researchers find that growth factor SCF promotes tumor angiogenesis by interacting with normal neurons, leading to worsened prognosis in patients. Decreased SCF expression improves survival in mouse glioma models, highlighting the importance of considering normal cells in cancer treatment.
Researchers have identified specific types of cancers that peak in incidence among teenagers and young adults, shedding light on potential causes. Infections, adolescent growth spurts, and hormonal factors are thought to contribute to the development of these cancers, with further research needed for conclusive evidence.
The BGEM Web site provides a growing collection of tens of thousands of images showing where and when specific genes are expressed during brain development. This information is linked to up-to-date data on genes, including their function, location, and DNA sequence.
Researchers found that donepezil significantly improved symptoms of short-term memory loss and mood changes in brain tumor patients who underwent radiation therapy. The study, published in the Journal of Clinical Oncology, suggests that donepezil may be effective in reducing symptoms associated with brain tumors and their treatments.
A study identifies molecular subclasses of high-grade gliomas that correlate with disease progression and prognosis. The subtypes resemble stages in neurogenesis, suggesting new insights for therapeutic intervention.
Gliadel Wafer demonstrates long-term survival benefit for patients with high-grade malignant glioma, increasing median survival to 13.9 months from 11.6 months. The treatment also shows a significant reduction in risk of death over the study period, with a 27% lower risk compared to placebo.
Researchers found that marrow-derived neural stem-like cells genetically engineered to produce interleukin-23 can track and destroy glioma cells, providing long-term immunity. This discovery offers a promising new therapeutic option for treating brain tumors.
A new study from the University of Michigan Medical School found that a particular surgical procedure, the middle cranial fossa (MCF) approach, can preserve hearing in patients with small acoustic neuromas. The study examined 73 patients and reported a high rate of success, with three-quarters retaining useful hearing after tumor removal.
L2G7 successfully causes brain tumor regression and improves animal survival in pre-clinical models. The monoclonal antibody targets key tumor growth factor hepatocyte growth factor (HGF), promoting cancer malignancy.
Researchers found space-time clustering of glioma tumour cases in different geographical locations, consistent with patterns caused by infections. The study suggests a possible link between infection and brain tumours, potentially leading to future preventative measures.
Researchers found that people exposed to loud noise over several years were 1.5 times more likely to develop acoustic neuroma, a slow-growing tumor that presses the cranial nerve responsible for sensing sound and balance. Wearing ear protection was associated with similar risk levels as non-exposure.
A new study found that hearing loss from chemotherapy is common in children treated with platinum agents, with 61% of patients experiencing some form of hearing loss. The study highlights the need for improved reporting and awareness of ototoxicity to prevent long-term development issues.
Researchers developed a treatment that targets glioblastoma cells using epidermal growth factor receptors (EGFR), eliminating tumors in mice implanted with human brain cancer cells. The therapy showed no evidence of recurrence and remained effective for over a year, offering new hope for GBM patients.
Researchers found that up to 70 percent of the water inside rapidly growing bacterial cells was generated by metabolism. This challenge to prevailing wisdom may lead to new methods for detecting fast-growing cancer cells or studying metabolic changes in obese individuals. The study's findings use stable isotope ratio mass spectrometry ...
The study found that the absence or presence of the Ink4c gene can help predict patient outcomes for medulloblastoma. Additionally, the collaboration between Ink4c and Ptch1 genes demonstrates the importance of gene dosage in mediating protective effects against tumorigenesis.
Researchers identified EGFRvIII and PTEN proteins as key factors in determining tumor response to EGFR inhibitors. These findings suggest that adjusting treatment based on genetic activity could significantly prolong life for glioblastoma patients and prevent unnecessary treatments.
A new therapeutic target has been identified in the inherited brain tumor disorder neurofibromatosis 1 (NF1). Fumagillin, an established drug, has been found to suppress the activity of MetAP2, which is abnormally high in NF1-associated brain tumors. This discovery may lead to new treatments for patients with NF1.
Researchers have discovered a novel treatment target in the protein EphA2, which plays a major role in the progression of brain tumors. The inactive form of this protein aids in cancer cell survival and spread.
Researchers at the University of Rochester Medical Center have successfully treated 72 patients with metastatic liver lesions using precision radiation therapy. The treatment resulted in a median survival time of 13 months, showing promise as an effective option for patients who previously had limited treatment options.
Researchers have developed a nanoparticle that can identify brain tumor cells and selectively target them for radiation therapy. The particles, called functional metallofullerenes, have shown promise in preliminary experiments and may one day benefit patients with advanced brain tumors.